• share
• favorite_border

鈥� Phase I trial demonstrates lasting responses and encouraging safety profile in two aggressive thyroid cancer subtypes, suggesting further progress for CAR T cell therapy in solid tumors 鈥� One patient experienced a complete response, and one patient had a partial response 鈥� This type of cancer has limited treatment options, and most patients have a poor prognosis of six months or less 鈥� AIC100 is a CAR T cell therapy that targets the ICAM-1 protein on tumor cells

• share
• favorite_border

The Society for Clinical Trials (SCT) is pleased to announce that the prestigious David Sackett Trial of the Year Award will be presented to 鈥淏linatumomab in Childhood Standard-Risk B-Cell Acute Lymphoblastic Leukemia.鈥�

• share
• favorite_border

Today, Penn Medicine celebrated the groundbreaking of the Roberts Proton Therapy Center at Penn Presbyterian Medical Center in University City, which is expected to open for patient care in late 2027.

• share
• favorite_border

路 LUT014, a topical BRAF inhibitor made by Lutris Pharma, is the first agent to treat the cause of the rash without interfering with the treatment itself 路 Over two-thirds of patients had successful treatment with the higher dose of LUT014 compared to one-third with placebo

• share
• favorite_border

鈥� RO7589831, a new drug from Roche, is first in a new class of drugs called Werner helicase inhibitors 鈥� Drug works similarly to other DNA damage repair inhibitors, such as PARP inhibitors 鈥� This class of drugs is important because many solid tumor patients with microsatellite instability (MSI) do not benefit from currently approved immunotherapies 鈥� Encouraging early results in this first-in-human trial prompted additional trial cohorts to optimize recommended dose for future clinical development

• share
• favorite_border

UCLA researchers demonstrated that a novel topical BRAF inhibitor gel called LUT014 significantly reduces the severity of an acne-like rash, a common and painful side effect experienced by patients undergoing anti-EGFR therapies for colorectal cancer.

• share
• favorite_border

New results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK), demonstrate how immunotherapy alone can allow people with MMRd cancers to avoid surgery and preserve their quality of life. The results, presented at the 2025 American Association of Cancer Research (AACR) Annual Meeting and published simultaneously in The New England Journal of Medicine (NEJM), found that 80 percent of patients did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone.

• share
• favorite_border

鈥� Combining Lynparza (olaparib) and Keytruda (pembrolizumab) showed antitumor activity in multiple cancer types, particularly those with BRCA1/2 mutations 鈥� Combination demonstrated complete responses and partial responses in different cancer types, including those beyond the currently approved indications for these therapies

• share
• favorite_border

An international phase 3 clinical trial led by Washington University School of Medicine in St. Louis and Dana-Farber Brigham Cancer Center shows that patients with certain locally advanced head and neck cancers benefited from the addition of the immunotherapy drug pembrolizumab (brand name Keytruda) to standard-of-care therapy. Patients who received pembrolizumab saw greater tumor shrinkage prior to surgery and, on average, survived cancer-free almost two years longer than did patients who only received standard-of-care therapy.

• share
• favorite_border

New research has shown that hypertensive individuals who maintain optimal control of several key health risk factors鈥攕uch as blood pressure, cholesterol, and lifestyle behaviors鈥攃an significantly reduce their risk of dying prematurely. The study found that with each additional risk factor brought under control, the risk of death from cancer, cardiovascular disease, and other causes dropped substantially. Most importantly, those who achieved high levels of joint risk factor control had no greater risk of early death than people without hypertension. This suggests that a comprehensive, multi-pronged approach to managing hypertension could effectively eliminate the excess mortality risk associated with the condition.

• share
• favorite_border

Patients with advanced non-small cell lung cancer (NSCLC) are often treated with immunotherapy drugs known as checkpoint inhibitors, which are designed to strengthen the immune system鈥檚 ability to kill cancer cells 鈥� but these drugs do not produce a lasting response in most patients with this cancer type.

• share
• favorite_border

Researchers from The University of Texas MD Anderson Cancer Center will present promising results from clinical trials in three minisymposia abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2025. Findings include a personalized vaccine combination therapy for colorectal cancer, the use of radiotherapy to avoid the toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancreatic cancer.

• share
• favorite_border

Researchers with UC San Diego Health identify a potential new treatment for uncontrolled high blood pressure.

• share
• favorite_border

Global competition in science and technology is intense. To continue to keep our nation secure, we must invest in breakthrough technologies through university research. In 2024, Tufts was awarded 30 patents. Many are now being commercialized

• share
• favorite_border

In a recent paper, published in Nature, researchers from the University of Michigan have discovered that simultaneously targeting PIKfyve and KRAS-MAPK can eliminate tumors in preclinical human and mouse models.

• share
• favorite_border

A new transatlantic collaboration between the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and LifeArc will look to develop an affordable and accessible monoclonal antibody therapeutic for Crimean-Congo Hemorrhagic Fever Virus (CCHFV), which could treat and protect thousands of people globally.

• share
• favorite_border

Researchers at UCLA Health are launching the first clinical trial to test whether a wearable device that delivers gentle nerve stimulation during sleep could ease ADHD symptoms in children with prenatal alcohol exposure.

• share
• favorite_border

Throughout Volunteer Appreciation Week, April 21-27, Cedars-Sinai is saluting its many outstanding volunteers and looking to add a few more to the corps.